US Drug Pricing Negotiations, Telehealth Flexibilities, 340B Pilot, and ACA Subsidies Update

House Democrats have proposed the Lowering Drug Costs for American Families Act (H.R. 6166), expanding the Inflation Reduction Act's drug price negotiation measures by increasing the annual number of negotiable drugs from 20 to 50 and extending negotiated pricing to commercial insurance plans, including those under the Affordable Care Act. The bill aims to cap insulin out-of-pocket costs at $35 monthly for commercial insurance holders and remove a loophole that allows certain drugs to evade negotiation by claiming orphan drug status. Additionally, it mirrors Medicare's inflation rebate penalties by applying them to the commercial drug market to curb excessive price increases. The Drug Enforcement Administration (DEA) is set to extend COVID-19 telemedicine flexibilities, enabling prescribers to continue issuing Schedule II-V controlled substances via telehealth without an initial in-person visit through 2026. This extension maintains current regulatory conditions while federal agencies work on establishing a permanent telehealth prescribing framework. The Health Resources and Services Administration (HRSA) has approved eight drug manufacturers' participation plans for the 340B Rebate Model Pilot, launching January 2026. This pilot shifts the 340B program from upfront drug discounts to post-purchase rebates on ten high-utilization drugs, aiming to increase transparency and address duplicate discounting. HRSA requires participating manufacturers to manage administrative costs and maintain detailed records. Despite some provider and bipartisan congressional advocacy for delaying the pilot, HRSA proceeds, framing it as foundational for future 340B reforms. A Senate Finance Committee hearing highlighted the debate over expiring enhanced Affordable Care Act subsidies and rising healthcare costs. Democrats support a one-year subsidy extension to prevent premium hikes, while Republicans propose expanding Health Savings Accounts as a cost-control alternative. Discussions also addressed employer-sponsored coverage premium growth and bipartisan interest in pharmacy benefit manager reform to improve drug pricing fairness. CMS has showcased a beta National Provider Directory prototype as part of its interoperability initiative to enhance data exchange and patient access across Medicare and other programs. However, the current Medicare Advantage provider directory has been criticized for inaccuracies and duplications, raising concerns among lawmakers and stakeholders about directory reliability and consumer impact. CMS faces pressure to improve directory accuracy as it progresses towards an authoritative national provider database.